What the FDA labels say about taking them together
Niacin and rosuvastatin
Rosuvastatin's FDA label of September 4, 2026 names niacin in its drug interactions section; niacin's label does not name rosuvastatin itself but warns about its class (Statins). The rosuvastatin label: “Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis.”
Check it at the source: the niacin FDA label on DailyMed (effective February 14, 2023, Aurobindo Pharma Limited); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the niacin label say about rosuvastatin?
Niacin's label does not name rosuvastatin itself; it warns about its class (Statins):
Niacin label, drug interactionsCaution should be used when prescribing niacin with statins as these agents can increase risk of myopathy/rhabdomyolysis.
Niacin label, drug interactionsCaution should be used when prescribing niacin (≥1 gm/day) with statins as these drugs can increase risk of myopathy/rhabdomyolysis [see Warnings and Precautions (5) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Niacin), Aurobindo Pharma Limited, effective February 14, 2023 (SPL set 43233a21-3f90-4c69-bbeb-f50d5f2d35ae), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about niacin?
Rosuvastatin label, drug interactionsPrevention or Management:; Consider if the benefit of using lipid-modifying dosages (≥1 g/day) of niacin concomitantly with rosuvastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of either drug.
Rosuvastatin label, warnings and precautionsNiacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1) ].
Crestor label (AstraZeneca Pharmaceuticals LP, April 29, 2026), drug interactionsNiacin Prevention or Management: Consider if the benefit of using lipid-modifying dosages (≥1 g/day) of niacin concomitantly with CRESTOR outweighs the increased risk of myopathy and rhabdomyolysis.
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Niacin | Rosuvastatin | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease, High triglycerides | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.193 per tablet 500 mg tablet | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once